세계의 페그필그라스팀 바이오시밀러 시장 : 부문별, 지역별

Global pegfilgrastim biosimilars market is estimated to be valued at USD 1.69 Bn in 2024 and is expected to reach USD 3.07 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Figure. Pegfilgrastim Biosimilars Market Share (%), By Region 2024

Pegfilgrastim is a long-acting form of filgrastim that stimulates the bone marrow to produce more white blood cells. Pegfilgrastim biosimilars are follow-on biologics or subsequent entry biologics of pegfilgrastim. These biosimilars have no clinically meaningful differences in terms of safety, purity, and potency from the original version of pegfilgrastim, when administered at the same dose. Biosimilars provide a cost-effective alternative to innovative biologics and expand access to important medicines for patients. Global pegfilgrastim biosimilars growth is driven by increasing demand for affordable treatment options and the patent expiration of innovator drugs, thus, leading to market entry of multiple biosimilars.

Market Dynamics:

Global pegfilgrastim biosimilars market growth is driven rising prevalence of cancer cases globally. Growing awareness about biosimilar drugs and government thrust on increasing affordability of treatment have boosted adoption of pegfilgrastim biosimilars. Lower costs compared to reference biologics also drives the market growth. However, presence of stringent regulations for biosimilar approval can pose challenge for market players. Data exclusivity granted to reference drugs also delays market entry of biosimilars. Furthermore, complex production processes and the need for specialized expertise can hamper the market growth. Presence of strong pipeline with various biosimilar approvals and emerging markets can offer opportunities for market growth.

Key features of the study

This report provides in-depth analysis of the global pegfilgrastim biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pegfilgrastim biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Amgen, AryoGen Pharmed, Coherus Biosciences, Mylan, Dr Reddy's Laboratories, and Biocon

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pegfilgrastim biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pegfilgrastim biosimilars market

Detailed Segmentation-

• By Product
  • Pegfilgrastim Biosimilars
  • Pegfilgrastim Reference Product
• By Application
  • Oncology
  • Chronic Neutropenia
  • Stem Cell Transplantation
  • Others
• By Route of Administration
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • CoherusBioSciences
  • Mylan N.V.
  • Biocon
  • Sandoz (a Novartis division)
  • Pfizer Inc.
  • Apotex Inc.
  • Cinfa Biotech
  • Gedeon Richter
  • StadaArzneimittel AG
  • Mundipharma
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals
  • Reddy's Laboratories
  • Intas Pharmaceuticals
  • Biocad
  • Genor Biopharma
  • Qilu Pharmaceutical
  • Henlius Biotech

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Application
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Pegfilgrastim Biosimilars Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Pegfilgrastim Biosimilars Market, By Product, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pegfilgrastim Biosimilars
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Pegfilgrastim Reference Product
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Pegfilgrastim Biosimilars Market, By Application, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Chronic Neutropenia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Stem Cell Transplantation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Pegfilgrastim Biosimilars Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cartridge
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Pegfilgrastim Biosimilars Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Pegfilgrastim Biosimilars Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • CoherusBioSciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
  • Biocon
  • Sandoz (a Novartis division)
  • Pfizer Inc.
  • Apotex Inc.
  • Cinfa Biotech
  • Gedeon Richter
  • StadaArzneimittel AG
  • Mundipharma
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals
  • Biocad
  • Genor Biopharma
  • Qilu Pharmaceutical
  • Henlius Biotech

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Research Methodology

• References
• Research Methodology
• About us and Sales Contact